Observation And Study On The Application Of Apatinib In Advanced Non-Small Cell Lung Cancer

Research background and purposeLung cancer is a common malignant tumor in China,but non-small cell lung cancer(NSCLC)accounts for most of it.There is no obvious symptom in the early stage of NSCLC,so most of the patients are in the late stage when the diagnosis is clear.At present,the clinical treatment methods of advanced non-small cell lung cancer include chemical drug treatment,radiation treatment,molecular targeted treatment,etc.in the long term,the common radiotherapy and chemotherapy have relatively large side effects and are prone to drug resistance.The new targeted drug has strong specificity,but it is only suitable for patients with gene mutation,and it has the same resistance as the traditional radiotherapy and chemotherapy.Apatinib,as an independent drug for angiogenesis in China,has been approved for the treatment of advanced gastric cancer.The mechanism of action of apatinib is that it can inhibit the activity of tyrosine kinase on VEGFR-2,because it can inhibit tumor angiogenesis,and ultimately inhibit tumor.In recent years,multiple studies have shown that apatinib has a significant effect in the treatment of advanced non-small cell lung cancer.research methodIn this study,45 patients with advanced non-small cell lung cancer(NSCLC)diagnosed by pathology in our hospital from 2017 to 2019 were retrospectively collected.The patients were split into two groups,including 22 patients in the apatinib treatment group and 23 patients in the chemotherapy-only group.Patients in the two groups were evaluated after treatment.The evaluation indexes were objective remission rate orr,disease control rate DCR and median progression free survival period mPFS.In addition,adverse reactions of patients after treatment were also evaluated.The administration mode of apatinib group: the administration mode of apatinib is internal administration,and the dosage starting from 500 mg is administered once a day.In case of adverse reactions,the dosage of the drug can be adjusted according to the situation ofthe patients.Continue to use until the evaluation of drug efficacy is the progress of the disease or the serious adverse reactions of the patients that lead to intolerability.The treatment method used in the chemotherapy group: single drug docetaxel 75 mg / ㎡ or gemcitabine 1000 / ㎡ is treated regularly according to the chemotherapy cycle,and the main information acquisition methods include: collection of relevant data of inpatient treatment and examination,outpatient examination data and telephone follow-up to obtain relevant information.To observe and study the whole treatment process of patients,including the time and dose of the two groups and the adverse reactions,as well as the regular examination of blood routine,urine routine,biochemical routine,Five tumor items,CT and other ways to evaluate the patient’s condition and the changes before and after the treatment of the tumor,and collect the adverse reactions caused by the medication And study,and provide relevant guidance and prevention for patients with adverse reactions.ResultA total of 45 patients with advanced non-small cell lung cancer were enrolled this time,including 22 in the apatinib treatment group and 23 in the chemotherapy-only group.In terms of efficacy,the mPFS was 4.3m in apatinib group and 3.2m in chemotherapy group.The data showed that both apatinib group and chemotherapy group could benefit from mPFS after the treatment of advanced NSCLC,and the benefit of apatinib group was greater than that of chemotherapy group,1.1m longer.In addition,the DCR of the apatinib group was 68.2%,while the DCR of the chemotherapy-only group was 39.1%,which was also better than that of the chemotherapy-only group(P<0.05).Among the comparison of adverse reaction data,the majority of the apatinib-treated group were hypertension,hand foot syndrome,anorexia,general asthenia and leukopenia.Compared with the chemotherapy group,the main adverse reactions were leukopenia,anorexia and asthenia.In the comparison of the occurrence probability of grade I-II adverse reactions,the occurrence probability of apatinib group was lower than that of chemotherapy group,and the adverse reactions in apatinib groupwere alleviated to a certain extent after symptomatic treatment,suggesting that the adverse reactions in apatinib group were mild and could be effectively controlled after treatment.In the comparison of the severity of adverse reactions,the number of adverse reactions in the group of apatinib is less than that in the group of chemotherapy alone,suggesting that the incidence of serious adverse reactions in the group of apatinib is lower.In general,the adverse reactions of apatinib were less serious than that of chemotherapy alone.conclusionIn the treatment of advanced non-small cell lung cancer,compared with chemotherapy alone,apatinib can significantly improve the prognosis of patients.Apatinib has less adverse reactions and higher safety than chemotherapy alone.